1. SENO MEDICAL INSTRUMENTS OPTO-ACOUSTIC SYSTEMS FOR MEDICAL IMAGING AND TOMOGRAPHY Alexander A. Oraevsky, Ph.D. Chief Scientific Officer, Seno Medical Instruments

2. OPTO-ACOUSTIC IMAGING TECHNOLOGY  Disruptive Technology for Unmet Needs  Multibillion Dollar Market  Platform for Multiple Follow-on Applications  Science Validated  Intellectual Property Protected Globally  Experienced Medical Device Management Team  Seeking Investment, Strategic Partners and Licensing Opportunities

3.  OA is a Natural Fusion of Optical Imaging (that provides high contrast) and Acoustic Imaging (that provides high resolution). OA allows to see under the skin in the depth of tissue based on detection of ultrasound waves generated through absorption of light  Opto-Acoustic Imaging is Disruptive Technology:  New medical information - maps of blood distribution in tissues and its oxygen saturation  First new functional imaging technology in 30 years: no contrast agents or ionizing radiation WHAT IS OPTO-ACOUSTIC IMAGING ?

4. micro-vasculature Mouse organs VALIDATION OF SCIENCE PRE-CLINICAL IMAGING IN ANIMALS: BRIDGE TO CLINIC blood vessels >$10M in US Government funding; >$30M for academic research worldwide

5. Cancer Cardiovascular Intravascular Stroke Brain Trauma Other Blood Related Applications 5 Diagnostic Imaging Image - Guided Biopsy Monitoring of Drug Efficacy Monitoring of Treatment Molecular and Functional Imaging PLATFORM TECHNOLOGY UTILIZING LIGHT AND SOUND TO MAP AND CHARACTERIZE BLOOD IN TISSUES AND IN ANGIOGENESIS-RELATED MICROVASCULATURE ~$40 B ~$10 B ~$35 B ~$10 B

6.  LOUIS combines optics and acoustics to significantly improve accuracy of cancer detection and noninvasive diagnosis ENTRY MARKET: BREAST CANCER

7. LOUIS™ IMAGING PROVIDES FUNCTIONAL INFORMATION ON BLOOD DISTRIBUTION IN ADDITION TO TISSUE STRUCTURE

8. OPTO-ACOUSTICS VERSUS CURRENT STANDARD OF BREAST IMAGING* Key Properties Gold Standard (X-ray mammo) LOUIS™ (US+OA) Significant Benefits Morphology and function Only morphology Yes Both High sensitivity and specificity Negative Predictive Value 70%/30% 50-70 y.o. / <40 y.o. 98% Lower Rate of Missed Cancer Positive Predictive Value 60%/20% 50-70 y.o. / <40 y.o. 82% Reduces False Positives Patient Safety Carcinogenic radiation Safe Light No harm to patients Patient Comfort Pain of compression No compression Patient acceptance *References: Geller BM. Vacek PM. Skelly J. Harvey SC. The use of additional imaging increased specificity and decreased sensitivity in screening mammography. Journal Clinical Epidemiology. 58(9):942-50. Sep 2005. Quing Z. Cronin EB. Currier AA. Vine HS. Huang M. Chen N. Xu C. Benign versus Malignant Breast Masses: Optical Differentiation with US-guided Optical Imaging Reconstruction. Radiology. 237: 57-66. Oct 2005.

9. Issued Patents  5,840,023 – The Core (umbrella) Opto-Acoustic Imaging Patent  6,309,352* – Treatment and Monitoring in Real-Time  6,498,942* – Distinguishing Malignant vs. Benign Tumors Allowed Patents  10 / 764,213 – Molecular Imaging Using Nanoparticles Published Patents  PCT / US06 / 02186 – Treatment Using Nanoparticles Pending Patents  11 / 656,103 – Methods of Quantitative Tomography * Licensed from the University of Texas Medical Branch Intellectual Property Protection

10. BEST-OF-BREED MANAGEMENT TEAM: KEY INDUSTRY EXPERIENCE and INFLUENCE  Janet Campbell – Chairman & CEO  Co-Founder of Seno Medical Instruments, Inc.  President & COO of InforMedix, Inc.  Alexander Oraevsky – Chief Scientific Officer  Inventor of opto-acoustic tomography  Vice President of R&D, Fairway Medical Technologies.  Ron Branstetter – President & COO  Co-Founder of Seno Medical Instruments, Inc.  President & COO of Colin Medical Instruments, Inc.  William Keane - Chief Medical Officer  Former Head of Merck & Co., Clinical Affairs and R&D

11. SCIENTIFIC ADVISORY COMMITTEE Seasoned Team of world class experts  Robert I. Kramer, M.D. – Susan G. Komen Advisory Board Founding Member  Charles Coltman, M.D. – Co-Founder of Cancer Therapy Research Center  Lester M. Crawford, D.V.M. – Former Head of the FDA  John W. Holaday, Ph.D. – Biotech entrepreneur; Among the 500 most cited scientists in the world  Patricia E. Sacks, M.D. – Director of the largest radiology practice in LA.  Tom Budinger, M.D., Ph.D. – Former president of Molecular Imaging Society; Leading expert in the field of biomedical imaging.  Walt Robb, Ph.D. – Founder of GE Medical Systems. Recipient of Medal of Technology the highest national honor for technological accomplishments from President Clinton.

12. FINANCIAL PROJECTIONS & KEY METRICS  Latest Seno Financial Projections Financials * ($)20092010201120122013 Revenues0011,57132,36569,470 Expenditures2,5557,77410,83121,95940,509 Net(2,555)(7,774)74010,40628,952 *(In Thousands (000) USD)

13. THE OPPORTUNITY  State of our Technology - validated through  Multimillion dollar grant funding  Research and publications by academia worldwide  Licensed our first commercial product for small animal imaging to Visual Sonics, worldwide leader in preclinical imaging research  IP protected globally and vetted for “freedom to operate”  Technology Advantages  First new functional imaging technology in decades  Provides high contrast, high resolution, real-time information  Provides structural and functional information for detecting, diagnosing and monitoring disease state  Opportunity  Looking for $3M in Bridge and 7.75 M in series B financing  Strategic partnerships for a variety of applications  Exit strategy – acquisition or IPO in 3 years